Patent · US Expired

Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same

US6825323B2 · kind B2 · utility

26Cited by
6References
30Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJan 10, 2001
Grant dateNov 30, 2004
Priority date—
Expiry dateJan 10, 2021

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/36
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The combination of recombinant factor VIIa and fibrinogen is effective in treatment for bleeding where direct pressure, tourniquets, indirect pressure, surgical ligation, bandaging, and transfusion of blood or plasma products are typically used. The combination of factor VIIa and fibrinogen is administered intravenously, either sequentially or simultaneously. The compositions may be safely circulated in the blood vessels to sites of injury. This is effective for single or multiple external or internal wounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.